Starlight Therapeutics

Starlight Therapeutics is an AI-driven biotech subsidiary of Lantern Pharma, singularly focused on addressing the high unmet need in CNS cancers. Its lead asset, STAR-001, is a small molecule drug candidate with orphan and rare pediatric disease designations, demonstrating promising preclinical data including excellent blood-brain barrier penetration and nanomolar potency. The company is preparing to initiate Phase 1b/2 clinical trials in multiple adult and pediatric indications following the completion of a Phase 1a safety study, positioning it in a multi-billion dollar market with limited effective therapies.

AI and machine learning platform (RADR® from Lantern Pharma) analyzing billions of genomic, molecular, and clinical data points for drug discovery, biomarker identification, and patient stratification, with a focus on blood-brain barrier permeability prediction.

The CNS oncology space is competitive with large pharma and biotech players, but effective therapies remain scarce, particularly for glioblastoma and brain metastases. Competition includes other targeted therapies, immunotherapies, and novel delivery technologies. Starlight's AI-driven precision approach and focus on BBB penetration aim to differentiate it from broader oncology companies.